Core Insights - Illumina's shares have increased by 44.8% over the past year, significantly outperforming the industry and S&P 500 [1][9] - The company is focused on long-term growth through its core sequencing business, multiomics expansion, and enhanced services, data, and software capabilities [2][4] Company Performance - Illumina's core sequencing business is experiencing growth, particularly with the NovaSeq X platform, which has driven a 7% increase in ex-China revenues in Q4 [4][9] - The company achieved its second-highest quarterly placements of NovaSeq X since its launch in 2023 [5] Strategic Initiatives - Illumina is expanding into multiomics through acquisitions, such as SomaLogic, and has launched the Illumina Connected Multiomics platform [6] - The introduction of the BioInsight business and the Billion Cell Atlas data product has garnered strong interest from biopharma partners [7] Financial Health - Non-GAAP gross margins improved by 165 basis points, and non-GAAP operating margins expanded by 400 basis points year-over-year [10] - As of the end of Q4, Illumina had cash and short-term investments totaling $1.63 billion, with $500 million in short-term debt, indicating a strong liquidity position [10] Market Challenges - In March 2025, China imposed a ban on imports of Illumina's NGS sequencers, which poses a significant challenge in a market with high sequencing demand [11] - The company is also facing macroeconomic pressures, including inflation and currency fluctuations [11] Future Projections - The Zacks Consensus Estimate predicts a 6.2% increase in EPS for 2026 and a 14.8% increase for 2027, with revenues expected to grow to $4.54 billion in 2026 and $4.83 billion in 2027 [12]

Core Insights - Patient Opportunity Equity Strategy achieved a return of 5.99% net of fees in Q4 2025, outperforming the S&P 500 Index which returned 2.65% [1] - The overall market experienced a strong year with a return of 17.9%, marking the seventh-best three-year period in market history [1] - The strategy outperformed the S&P 500 for the third consecutive year with a total return of 26.1% in 2025 [1] Company Focus: Illumina, Inc. (NASDAQ:ILMN) - Illumina, Inc. is a biotechnology company specializing in sequencing and array-based solutions for genetic and genomic analysis [2] - As of March 04, 2026, Illumina's stock closed at $128.97 per share, with a one-month return of -3.47% and a 52-week gain of 52.36% [2] - The company has a market capitalization of $19.72 billion [2] Performance and Outlook - Illumina was a top contributor in Q4 2025, driven by a stronger-than-expected third-quarter earnings report, with growth in clinical consumables exceeding expectations [3] - The core sequencing business is returning to a normalized growth and profitability profile, with improving confidence in demand durability and margin recovery [3] - Illumina reported revenue of $1.16 billion in Q4 2025, reflecting a 5% year-over-year increase on a reported basis and 4% on a constant currency basis [4] Hedge Fund Interest - Illumina is not among the 40 most popular stocks among hedge funds, with 46 hedge fund portfolios holding the stock at the end of Q4 2025, up from 45 in the previous quarter [4]

Core Message - The company successfully showcased its product roadmap at the AGBT conference, emphasizing its commitment to innovation and customer success [2] Group 1: Product Roadmap - The focus was on demonstrating the NovaSeq X, which has been a significant success, along with plans for additional flow cells to enhance customer offerings [2] Group 2: Competitive Landscape - The company highlighted its strategy to ensure continued innovation, positioning itself favorably against competitors like Roche [2]

Illumina FY Conference Summary Company Overview - **Company**: Illumina (NasdaqGS:ILMN) - **Event**: FY Conference at TD Cowen Global Healthcare Conference - **Date**: March 03, 2026 Key Industry Insights - **Product Roadmap**: Illumina showcased its innovation strategy at the AGBT conference, emphasizing the NovaSeq X platform and its capabilities for both high and low capacity applications [4][5] - **TruPath Technology**: Launched as a library prep solution that eliminates traditional library preparation time, allowing for genome sequencing at a cost of $395, which is positioned as the lowest price for high-quality genome sequencing [6][7] - **Spatial Technology**: Illumina is advancing spatial technology to analyze larger tissue samples, which has generated significant customer interest [8][9] - **Competitive Landscape**: Illumina acknowledges competition from Roche, highlighting differences in workflow and pricing models, and expresses confidence in its ability to compete effectively [11][12] Financial Guidance - **Growth Projections**: For 2026, Illumina projects organic growth of 1%-3% excluding China, with a potential upside if the clinical business performs better than expected [30][31] - **Operating Margin**: Targeting a 150 basis point improvement in operating margin, aiming for a 26% operating margin in the near future [31][32] - **Earnings Per Share (EPS)**: Anticipating double-digit growth in EPS, despite headwinds from the SomaLogic acquisition [32] Market Dynamics - **Clinical vs. Research**: The clinical segment is expected to drive growth, particularly in oncology, with a shift towards minimal residual disease (MRD) detection and early cancer detection [43][44] - **Research Challenges**: The research segment faces ongoing pressures, but Illumina remains optimistic about maintaining high single-digit growth in a competitive environment [52] Product Innovations - **Q70 Scores**: Illumina plans to introduce Q70 scores for high sensitivity MRD applications within the next 18 months, which is expected to enhance clinical applications [5][58] - **Protein Prep**: The acquisition of SomaLogic is expected to expand Illumina's capabilities in protein analysis, with a focus on reducing costs and increasing the number of proteins analyzed [64][68] - **BioInsight**: A new initiative aimed at creating large datasets for AI model training in biology, which will be monetized through subscriptions to pharmaceutical companies [92][96] Competitive Positioning - **Roche Comparison**: Illumina believes it is well-positioned against Roche, particularly with the TruPath technology, which offers unique insights and a simpler workflow compared to Roche's offerings [100][101] - **Market Sentiment**: Illumina's leadership expresses confidence in its competitive edge, citing strong R&D and commercial teams as key advantages [108] Conclusion - **Future Outlook**: Illumina is committed to strong growth in a competitive landscape, with a focus on innovation and customer success in both clinical and research applications [108]

Core Insights - Illumina has announced significant breakthroughs in oncology through the use of its multiomics solutions, including spatial transcriptomics, 5-base sequencing, and proteomics technologies, which enhance precision diagnostics and targeted therapeutics development [1][2] Group 1: Multiomics Solutions - The integration of multiple omic insights provides unprecedented biological depth, enabling researchers to achieve breakthroughs in oncology and pharmacogenomics [1] - Illumina's Connected Multiomics platform streamlines multimodal data analysis, facilitating a deeper understanding of tumor microenvironments [1] Group 2: Spatial Technology - Illumina Spatial Technology has been utilized to decode complex tissues, such as the human lymphatic system, improving cancer diagnosis and prognosis [1] - Research using Illumina Spatial Technology has produced the first whole transcriptome spatial datasets for human lymphatic collector vessels, aiding in the understanding of lymphatic vessel functions [1] Group 3: 5-Base Sequencing - The 5-base solution has been applied in pediatric kidney cancer research, allowing for simultaneous genomic and methylation profiling, which enhances diagnostic accuracy [1][2] - This solution has successfully identified cases of rhabdoid tumors that were missed by conventional genomic methods, indicating its potential for improving patient outcomes [1] Group 4: Ovarian Cancer Research - Illumina's technologies have enabled researchers to differentiate between cancerous and benign tumor types in ovarian cancer, creating a multiomic framework for future research [2] - The combination of 5-base sequencing and Illumina Protein Prep has led to the identification of novel gene sets and pathways in ovarian cancer, opening new avenues for biomarker and drug development [2] Group 5: Advancements in Diagnostics - The integration of multiomics analytics provides deeper insights into cancer mechanisms and tumor heterogeneity, which can lead to the identification of new therapeutic targets [2] - Illumina's Connected Multiomics accelerates the sample-to-answer pipeline, overcoming challenges associated with isolated assays [2]

Core Insights - Illumina has announced an 18-month roadmap for the NovaSeq X system, focusing on advancements in data quality, output, speed, and flexibility, which will enhance precision medicine and provide compounded value for customers [1] Group 1: Product Enhancements - The NovaSeq X system will see a 40% increase in output, reaching 35 billion reads, and will introduce Q70 quality scores for the first time [1] - Speed improvements will result in a 30% increase, allowing for 14 billion outputs in 20-22 hours [1] - New flow cells and staggered starts will be implemented, enhancing batching flexibility and optimizing flow cell usage for various applications [1] Group 2: Market Impact - These updates are expected to significantly increase daily sequencing productivity and expand the range of applications that can be performed on a single instrument [1] - The advancements will support research in oncology and rare diseases, improving the accuracy and efficiency of molecular residual disease testing and genetic disease research [1] Group 3: Customer Feedback - Texas A&M Agri Life reported a 30% increase in data yield since acquiring the NovaSeq X, highlighting the system's improved performance for high-throughput sequencing [1]

Financial Data and Key Metrics Changes - Illumina reported Q4 revenue of $1.16 billion, up 5% year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [26] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with 11% growth excluding China [22] - Research and applied markets consumable sales were roughly flat year-over-year, reflecting ongoing uncertainty in the funding environment [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, representing a $25 million decline from Q4 of 2024 [22] - Clinical market maintained momentum, growing 20% outside of China, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew at a rate of more than 30% year-over-year, primarily from clinical customers [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][13] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid-to-high single digits [30][31] - Management highlighted the importance of adapting to the evolving market dynamics and customer needs, particularly in the clinical space [16][70] Other Important Information - Illumina returned approximately $740 million to shareholders through share repurchases in 2025 [7] - The company ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The acquisition of SomaLogic was completed for an upfront payment of $350 million, with potential royalties and milestone payments [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and discussed capital deployment priorities [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of NovaSeq X placements were to clinical customers, with expectations for this trend to continue [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various diseases [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and the ability to address market segments with different pricing strategies [74][76] Question: China market assumptions and BioInsight monetization - Management discussed ongoing conversations with Chinese regulators and the potential for growth in the BioInsight business, emphasizing its early-stage momentum [80][81]

Financial Data and Key Metrics Changes - Illumina reported Q4 2025 revenue of $1.16 billion, a 5% increase year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, reflecting a 42% year-over-year growth [26] - Non-GAAP operating margin expanded to 23.7%, up 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% in Q4 2025, excluding China, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue reached $755 million, an 8% increase year-over-year [22] - Research and applied markets consumable sales were roughly flat year-over-year, indicating a stabilization compared to previous quarters [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting ongoing export restrictions [22] - Clinical market growth outside of China was 20%, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew over 30% year-over-year, primarily from clinical applications [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [11][12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [30][31] - Management highlighted the importance of adapting to the evolving funding environment in the research sector [44] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [7] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The company plans to continue share repurchases opportunistically, with $643 million remaining on its authorization [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth momentum [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various applications [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and highlighted ongoing discussions with customers regarding pricing and workflow efficiencies [74][76]

Financial Data and Key Metrics Changes - In Q4 2025, Illumina's revenue reached $1.16 billion, reflecting a 5% year-over-year increase on a reported basis and a 4% increase on a constant currency basis [18][19] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [24] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [23] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [4][19] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with a notable 11% increase excluding China [19] - Sequencing instruments revenue was approximately flat year-over-year at $154 million, with strong placements of NovaSeq X [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting export restrictions [19] - Clinical market outside China grew 20%, driven by broader adoption of NGS-based testing [19] - Research and applied markets saw consumable sales remain roughly flat year-over-year, indicating ongoing uncertainty in the funding environment [20] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [9][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities to accelerate innovation [10][11] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in the second half of 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [15][27] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [15][29] - Management highlighted the importance of adapting to evolving market dynamics and customer needs, particularly in the context of multi-omics [14][78] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [5] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents, maintaining a strong balance sheet [25] - The company plans to change geographical reporting segments starting in Q1 2026 to better align with its commercial structure [31] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [33][36] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects continued momentum in clinical growth, with expectations for mid-teens growth, while acknowledging challenges in the research environment [40][42] Question: Instrumentation split between research and clinical - Over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [46][48] Question: Growth drivers in oncology and genetic applications - Oncology is expected to remain the main growth driver, with significant uptake in genetic profiling for various diseases [62][64] Question: BioInsight monetization strategy - Management outlined plans for monetizing BioInsight through specialized data and subscription-based models, indicating a multi-year opportunity [78][79]

Q4 2025 Earnings Presentation February 5, 2026 © 2026 Illumina, Inc. All rights reserved. Cautionary Notes Year-over-year (YoY) denotes a comparison against the same quarter of the previous fiscal year, while quarter-over-quarter (QoQ) or "sequential" denotes a comparison against the previous fiscal quarter. In addition, all references to China refer to our Greater China Region, which also includes Taiwan and Hong Kong. © 2026 Illumina, Inc. All rights reserved. 2 RGB: 229, 96, 0 RGB: 228, 189, 255 RGB: 255 ...